GLP-1 drugs

Novo Nordisk A/S (NYSE:NVO) has lost more than half its value from its peak. NVO stock is down 58% over the past year and more than 40% in just the past month, collapsing from a 52-week high of $91.90 to near $38. But beneath the selloff, something unusual has emerged. Novo Nordisk is no longer...

Novo Nordisk A/S' (NYSE:NVO) weight-loss revolution just swallowed a record. In just its second week on the market, Novo Nordisk's oral Wegovy pill hit 20,371 prescriptions, up from 4,289 in week one—a nearly 500% week-over-week surge. For context, Eli Lilly And Co's (NYSE:LLY) Zepbound hit about...

Linda Yaccarino may have a resume that many people around the world envy. In the past two years, Yaccarino has worked for Elon Musk and is now Tom Brady's boss. • Novo Nordisk stock is facing resistance. Why is NVO stock trading lower? Tom Brady Joins Telehealth Startup eMed In 23 seasons in...

Stanley Druckenmiller's Viking Therapeutics Inc (NASDAQ:VKTX) bet is starting to look like a classic Druckenmiller move — quietly bold, impeccably timed, and now technically validated. The billionaire investor's family office took a fresh position in VKTX during the second quarter, buying roughly...

Ozempic and Zepbound have morphed from diabetes treatment into a cultural phenomenon, helping Novo Nordisk A/S (NYSE:NVO) and Eli Lilly And Co (NYSE:LLY) achieve a combined market cap topping $900 billion. Celebrities flaunt it, Silicon Valley elites swear by it, and analysts predict the GLP-1...

Novo Nordisk A/S (NYSE:NVO) may have found a timely catalyst. From the lows of its 52-week trading range, the Danish drugmaker is showing signs that a bullish comeback might be on the horizon—driven by both regulatory approval momentum and technically solid market signals. The firm’s shares...

The rise of cash-pay GLP-1 prescriptions, fueled by programs like LillyDirect, is generating plenty of buzz—but JPMorgan analyst Lisa C. Gill isn't convinced this is a major shake-up for the healthcare supply chain. According to Gill, while Eli Lilly And Co's (NYSE:LLY) direct-to-consumer push is...

Novo Nordisk AS (NYSE:NVO) will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours. The stock is up 8.55% over the last year and 7.45% year-to-date. Let’s look at what the charts indicate...

Viking Therapeutics Inc. (NASDAQ:VKTX) is set to report its third-quarter earnings on Wednesday, after the market closes. The anticipation is palpable, especially as the stock has skyrocketed almost 240% year-to-date, largely due to excitement surrounding its weight-loss drug candidate, VK2735. As...

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own versions of blockbuster weight loss drugs. What Happened: The FDA on Friday said in a court filing...

JPMorgan analyst Hardik Parikh initiated coverage on Viking Therapeutics Inc (NASDAQ:VKTX) with an Overweight rating and a December 2025 price target of $80, which implies a potential 45% upside from its current price of $54.65. At the core of this bullish outlook is Viking’s obesity drug...

In a recent tweet, Bernie Sanders (I-Vt.) criticized the pricing of a popular diabetes drug, Ozempic, and its manufacturer, Novo Nordisk A/S (NYSE:NVO). What Happened: Sanders took to X, formerly Twitter, on Wednesday to express his concerns about the pricing of Ozempic. He suggested that the drug...

The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning...

Mangoceuticals, Inc. (NASDAQ:MGRX) shares are trading higher Tuesday after the company announced the development of oral formulations of Semaglutide and Tirzepatide. The Details: Mangoceuticals announced the development of proprietary oral formulations of Semaglutide (“Slim”) and...

Stocks made new record highs, with the S&P 500 reaching a closing high of 5,137.08 and an intraday high of 5,140.33 on Friday. For the week, the S&P gained 1%. The index is now up 7.7% year to date and up 43.6% from its October 12, 2022 closing low of 3,577.03. In the markets and the...